Bli medlem
Bli medlem

Du är här


Redeye: AroCell - A Closer Look at the Acquisition

Redeye returns with a more in-depth view on AroCell’s acquisition of IDL Biotech, seeing a new case with more substantial commercial opportunities in the short to medium term, despite TK210 ELISA’s US prospects taking a beating. We reassess our estimates and update our fair value range, which is considerably higher than the current share price. Still, skepticism toward the stock is likely to persist owing to the recent FDA disappointment.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.


AroCell - A Closer Look at the Acquisition

Författare MFN